Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2)

Next Previous
Trial Profile

Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary) ; Aspirin
  • Indications Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms RESPONSE-2
  • Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals

Most Recent Events

  • 12 Dec 2023 Results of pooled analysis of RESPONSE and RESPONSE 2 describing patient benefit of ruxolitinib in patients with PV with or without splenomegaly,presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 13 Dec 2022 Results of a study assessing changes of JAK2V617F variant allele fraction in PV and ET patients who were long-term treated with ruxolitinib from tow clinical studies: REPSONSE-1 and RESPONSE-2 presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top